In a prepared statement, AbCellera founder and chief executive Carl Hansen said Health Canada had granted authorization for the use of bamlanivimab to treat people over the age of 12 with mild and moderate COVID-19 symptoms who were at high risk of the disease progressing.
AbCellera is entitled to receive a specified percentage of proceeds that Lilly receives from these sales. According to Bloomberg News, AbCellera is expected to be worth several billion dollars after it is publicly listed. AbCellera researchers used a blood sample from one of the earliest COVID-19 survivors from the U.S. to get their work started.
According to Latest 2nd Wave Numbers. 0.7117% of Ontario's Population has Tested Positive to Date (up from 0.7012%) That Leaves Only 99.2882% Having Not Tested Positive (down from 99.2987%) MSMDefcon101 😜🎈🤡❄️ ArmageddonWatchzzzz
And wasn’t this drug used on Trump, no mention of that from MSM